{"id":"NCT00171873","sponsor":"Carmen Schade-Brittinger","briefTitle":"Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut","officialTitle":"Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-09","primaryCompletion":"2008-06","completion":"2013-12","firstPosted":"2005-09-15","resultsPosted":"2011-03-28","lastUpdate":"2020-03-26"},"enrollment":85,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Neuroendocrine Tumors"],"interventions":[{"type":"DRUG","name":"Octreotide LAR (Long-acting release)","otherNames":["SMS995"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Octreotide LAR (Long Acting Release)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Placebo-controlled prospective randomized phase III study to investigate the antiproliferative effect of octreotide in patients with metastasized neuroendocrine tumors of the midgut","primaryOutcome":{"measure":"Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)","timeFrame":"Up to 7 years","effectByArm":[{"arm":"Octreotide LAR (SMS995)","deltaMin":14.3,"sd":null},{"arm":"Placebo","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":10,"countries":["Germany"]},"refs":{"pmids":["19704057"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":42},"commonTop":["Gastrointestinal disorders","General Health","Hematopoietic system"]}}